The Latest Analyst Ratings For Legend Biotech
The Latest Analyst Ratings For Legend Biotech
傳奇生物的最新分析師評級
In the preceding three months, 15 analysts have released ratings for Legend Biotech (NASDAQ:LEGN), presenting a wide array of perspectives from bullish to bearish.
在過去三個月中，共有15名分析師發佈了關於傳奇生物（納斯達克股票代碼爲LEGN）的評級，提供了從看好到看淡的廣泛觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $78.93, a high estimate of $90.00, and a low estimate of $60.00. Highlighting a 2.56% decrease, the current average has fallen from the previous average price target of $81.00.
分析師所分析的12個月股價目標提供了洞察力，平均目標爲78.93美元，高估值爲90.00美元，低估值爲60.00美元。當前平均值降低2.56%，從之前的81.00美元的平均股價目標下降。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：更深入的了解
In examining recent analyst actions, we gain insights into how...
通過分析最近的分析師...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。